Oncology Central

A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy

0

Aims: The activity of the transcription factor c-Myc is dependent upon heterodimerization with Max to control target gene transcription. Small-molecule inhibitors of c-Myc–Max have exhibited low potency and poor water solubility and are therefore unsuitable for in vivo application. We hypothesized that a nanomedicine approach incorporating a cryptic c-Myc inhibitor prodrug could be delivered and enzymatically released in order to effectively inhibit melanoma.

To view restricted content, please:
Share:

Leave A Comment